Impact of 18F-FDG PET/CT on target volume delineation in recurrent or residual gynaecologic carcinoma

Exploring the impact of metabolic imaging in head and neck cancer treatment

Background

Target volume delineation is performed with anatomical imaging for head and neck cancer. Molecular imaging allows the recognition of specific tumor regions. Its inclusion in the pathway could lead to changes in delineation and resultant treatment plans.

Methods

PRISMA methodology was adhered to when selecting the articles for analysis and only full articles were quality assessed.

Results

Seventeen articles were included. Gross tumor volume (GTV) primary, GTV nodal, and other target volumes were evaluated. Positron emission tomography/computerized tomography (PET/CT) produced smaller primary GTVs, although not with diffusion‐weighted imaging‐magnetic resonance imaging (DWI‐MRI) or PET/MRI. The impact of these image modalities on GTV nodal did not display any consistency. Additionally, there was considerable heterogeneity in metrics comparing delineations. Four studies included appraised the dosimetric impact of the changes in target volume delineation.

Conclusion

Quantifying the impact of molecular imaging is difficult, due to heterogeneity in reporting metrics in molecular imaging modalities and a paucity of detail regarding delineation method and guideline adherence.

Evaluating the Use of 18F-FDG PET CT for External Beam Radiotherapy Planning in Gynaecological Malignancies

PURPOSE OF REVIEW

To evaluate the evidence for the use of fluorine-18-fluorodeoyglucose (18F-FDG) PET CT in external beam radiotherapy planning for treatment of gynaecological malignancies.

RECENT FINDINGS

Our review confirms that the incorporation of 18F-FDG PET CT during radiotherapy planning may decrease inter-observer variability during target delineation. It can also provide useful functional information regarding the tumour, which may facilitate the development of techniques for dose escalation and 'dose painting' not only for primary disease, especially in cervical cancer, but also nodal metastasis. The utilisation of this functional modality in external beam radiotherapy planning, particularly in locally advanced cervical malignancy, is an exciting topic that warrants further prospective research. Perhaps the most valuable role may be the potential to deliver dose escalation to 18F-FDG PET CT avid targets previously limited by organ at risk constraints, now that we have significantly more advanced radiotherapy planning tools at our disposal.

Treatment results of image-guided high-dose-rate interstitial brachytherapy for pelvic recurrence of uterine cancer

PURPOSE

We analyzed clinical data to evaluate the effectiveness of image-guided high-dose-rate interstitial brachytherapy (HDR-ISBT) for pelvic recurrence of uterine cancer.

METHODS AND MATERIALS

Between 2003 and 2011, 56 patients were treated with HDR-ISBT with or without external beam radiotherapy (EBRT). The median followup time was 33 months (range, 1-109 months). Pre-ISBT treatments included radical hysterectomy for 35 patients (Group A), radical hysterectomy with postoperative radiotherapy for 8 patients (Group B), and radical radiotherapy for 13 patients (Group C). We initiated MRI-assisted CT-based planning for the last 49 patients. The median ISBT single fraction dose was 6 Gy. The median total doses were 30 and 54 Gy with and without EBRT (range, 30-50 Gy) for Group A, respectively and 48 Gy without EBRT for Groups B and C.

RESULTS

The 3-year local control (LC) rates were 85%, 75%, and 46% for Groups A, B, and C, respectively (p = 0.017). The 3-year LC rates were 84%, 73%, and 33% for clinical target volume at the time of HDR-ISBT of <10, 10-29, and ≥30 cc, respectively (p = 0.005). The 3-year LC results tended to be higher for patients whose D100 (clinical target volume) was equal or higher than 67.1 Gy (p = 0.098). A total of 13 late complications of Grades 3-5 occurred in 11 patients (20%).

CONCLUSIONS

Our image-guided HDR-ISBT for pelvic recurrence of uterine cancer provided good treatment outcomes. The treatment results for patients who underwent radical surgery with or without postoperative radiotherapy are better than those for patients who underwent radical radiotherapy.

Comparison of Tumor Volume Between PET and MRI in Cervical Cancer With Hybrid PET/MR

Objective

This study aimed to compare the tumor volume between magnetic resonance imaging–defined gross tumor volume (MR-GTV) and positron emission tomography–defined GTV (PET-GTV) in cervical cancer with hybrid PET/MR.

Materials and Methods

Twenty-seven patients with cervical cancer underwent PET/MR pelvic examination before radiotherapy. The MR-GTV was manually outlined on T2-weighted MR images. The PET-GTV was autocontoured on PET images using a 40% maximum standardized uptake value threshold. Results were analyzed by Pearson analysis, Bland-Altman plot, and 1-way analysis of variance.

Results

Magnetic resonance imaging–GTV significantly correlated with PET-GTV (r2 = 0.797, P < 0.001). The Bland-Altman plot showed a bad agreement between MR-GTV and PET-GTV. The PET-GTV underestimated the MR-GTV in 23 of 27 tumors. Patients were divided into the following 3 groups according to MR-GTV: less than 14 mL (n = 6), 14 to 62 mL (n = 12), and 62 mL or more (n = 9). The mean (SD) MR-GTV, PET-GTV, ratio, and overlap between MR-GTV and PET-GTV for the less than 14 mL cohort were 9.6 (2.6) mL, 16.7 (10.1) mL, 0.77 (0.40), and 0.47 (0.20), respectively. The PET-GTV overestimated MR-GTV in 4 of the 6 lesions by a mean (SD) of 11.1 (9.4) mL. Among the 14 to 62 mL cohort, the mean (SD) MR-GTV, PET-GTV, ratio, and overlap were 38.6 (14.5) mL, 24.9 (8.6 mL), 1.54 (0.25), and 0.87 (0.08), respectively. The PET-GTV underestimated MR-GTV for 12 tumors by a mean (SD) of 13.7 (8.4) mL. In the 62 mL or more cohort, the mean (SD) MR-GTV, PET-GTV, ratio, and overlap were 85.9 (25.8) mL, 54.3 (14.1) mL, 1.61 (0.35), and 0.87 (0.09), respectively. The PET-GTV underestimated MR-GTV 9 tumors by a mean (SD) of 31.6 (19.5) mL. The ratio and overlap differences were statistically significant among groups (F = 14.619, P < 0.001; F = 25.134, P < 0.001).

Conclusions

Tumor volume discrepancies were observed between MR-GTV and PET-GTV for cervical cancer. With an increasing tumor volume, there was an increase in the difference between MR-GTV and PET-GTV. In addition, larger tumors had a higher degree of overlap compared with small tumors.

Visualization, imaging and new preclinical diagnostics in radiation oncology

Innovative strategies in cancer radiotherapy are stimulated by the growing knowledge on cellular and molecular tumor biology, tumor pathophysiology, and tumor microenvironment. In terms of tumor diagnostics and therapy monitoring, the reliable delineation of tumor boundaries and the assessment of tumor heterogeneity are increasingly complemented by the non-invasive characterization of functional and molecular processes, moving preclinical and clinical imaging from solely assessing tumor morphology towards the visualization of physiological and pathophysiological processes. Functional and molecular imaging techniques allow for the non-invasive characterization of tissues in vivo, using different modalities, including computed tomography (CT), magnetic resonance imaging (MRI), ultrasound, positron emission tomography (PET) and optical imaging (OI). With novel therapeutic concepts combining optimized radiotherapy with molecularly targeted agents focusing on tumor cell proliferation, angiogenesis, and cell death, the non-invasive assessment of tumor microcirculation and tissue water diffusion, together with strategies for imaging the mechanisms of cellular injury and repair is of particular interest. Characterizing the tumor microenvironment prior to and in response to irradiation will help to optimize the outcome of radiotherapy. These novel concepts of personalized multi-modal cancer therapy require careful pre-treatment stratification as well as a timely and efficient therapy monitoring to maximize patient benefit on an individual basis. Functional and molecular imaging techniques are key in this regard to open novel opportunities for exploring and understanding the underlying mechanisms with the perspective to optimize therapeutic concepts and translate them into a personalized form of radiotherapy in the near future.

Automated biological target volume delineation for radiotherapy treatment planning using FDG-PET/CT

BACKGROUND

This study compared manually delineated gross tumour volume (GTV) and automatically generated biological tumour volume (BTV) based on fluoro-deoxy-glucose (FDG) positron emission tomography (PET)/CT to assess the robustness of predefined PET algorithms for radiotherapy (RT) planning in routine clinical practice.

METHODS

RT-planning data from 20 consecutive patients (lung- (40%), oesophageal- (25%), gynaecological- (25%) and colorectal (10%) cancer) who had undergone FDG-PET/CT planning between 08/2010 and 09/2011 were retrospectively analysed, five of them underwent neoadjuvant chemotherapy before radiotherapy. In addition to manual GTV contouring, automated segmentation algorithms were applied-among these 38%, 42%, 47% and 50% SUVmax as well as the PERCIST total lesion glycolysis (TLG) algorithm. Different ratios were calculated to assess the overlap of GTV and BTV including the conformity index and the ratio GTV included within the BTV.

RESULTS

Median age of the patients was 66 years and median tumour SUVmax 9.2. Median size of the GTVs defined by the radiation oncologist was 43.7 ml. Median conformity indices were between 30.0-37.8%. The highest amount of BTV within GTV was seen with the 38% SUVmax algorithm (49.0%), the lowest with 50% SUVmax (36.0%). Best agreement was obtained for oesophageal cancer patients with a conformity index of 56.4% and BTV within GTV ratio of 71.1%.

CONCLUSIONS

At present there is only low concordance between manually derived GTVs and automatically segmented FDG-PET/CT based BTVs indicating the need for further research in order to achieve higher volumetric conformity and therefore to get access to the full potential of FDG-PET/CT for optimization of radiotherapy planning.